MedTrace Logo

Recombinant Versus Highly Purified FSH in Polycystic Ovary Syndrome (PCOS)

NCT01337531 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2011-04-19

No results posted yet for this study

Summary

Control ovarian stimulation responses, pregnancy and miscarriage rates are indifferent when either recombinant or highly purified follicle stimulating hormone (FSH) is used.

Conditions

  • Polycystic Ovary Syndrome

Interventions

DRUG

Gonal-F, Fostimon

dosage form

DRUG

Gonal-F, Fostimon

injection, daily, 10-15 days

Sponsors & Collaborators

  • Genesis Center for Fertility & Human Pre-Implantation Genetics

    lead OTHER

Principal Investigators

  • Savvas N Koundouros, PhD · Genesis Center for Fertility and Human Pre-implantation Genetics

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-05-31
Primary Completion
2011-11-30
Completion
2011-12-31

Countries

  • Cyprus

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01337531 on ClinicalTrials.gov